In a multi-institutional study published in ScientificResearchers revealed that testing urine-based tumors DNA (UTDNA) can help to estimate which bladder cancer patients are at greater risk for recurrence after treatment.

This study analyzed UTDNA from patients in the Swog S1605 test, which was treated with ATEZOLIZUMAB, A. immunotherapy Medicine. Researchers used URAPP tests to examine urine samples from 89 patients at the beginning of treatment and three months later from 77 patients. The goal was to see if Utdna can help identify which bladder cancer patients are most likely to respond to immunotherapy.

This approach can help improve the patient’s care by guiding more effective treatments and supporting more personal plans. This means that we may be able to do medical treatment soon, reduce unnecessary delays and help patients to avoid major surgery without compromising their care. ,

Robert Swatek, MD, MSCI, Joe R. at Texas Health Science Center at San Antonio (UT Health San Antonio).

UT Health San Antonio is a national level recognized urological oncologist, Svatek, a leading expert in bladder cancer and a member of SWOG, also known as a Southwest oncology Group. SWOG National Cancer Institute (NCI) is part of the National Clinical Trial Network (NCTN) and one of the five major cancer clinical testing groups in the United States.

SWOG S1605 Study was a stage 2 clinical test test in high-risk bladder cancer patients, which did not respond to BCG (Basilus Calmet-Gren) treatment, which was the main immunotherapy for the treatment of early stage bladder cancer.

Samples were collected from the participants before treatment and again three months later. Researchers use Uroamp assay, a non-invasive urine test that detects mutation related to bladder cancer, analyzing Utdna and generating a genomic profile for each patient.

He found that the level of UTDNA was connected to how well the patients reacted after six months and in 18 months they remained cancer-free. Patients with positive UtDNA results were less likely to respond and their cancer was more likely to return.

According to the American Cancer Society, bladder cancer is the sixth most common cancer in the United States, diagnosing more than 83,000 new cases annually. Out of these cases, about 75% of non -masculinity are aggressive, meaning that cancer has not yet invaded the bladder muscles.

Patients who do not respond to immunotherapy can either withstand the difficult decisions of continuous remedies that leave the bladder, but carry high risks of recurrence or undergo major surgery that removes the bladder and affects someone in depth.

The study provides new expectation for high-risk bladder cancer patients, showing that urinary-based DNA testing can help estimate who is more likely to benefit from immunotherapy. At the beginning of the reaction of treatment, this approach can guide more individual, bladder-protection care and reduce the need for major surgery.